Synthesis of multi-labeled [14C]Aripiprazole

• Published in: Journal of labelled compounds & radiopharmaceuticals Vol. 49; no. 1; pp. 1 - 9
• Main Authors: Bonacorsi Jr, Samuel J., Waller, Stephen C., Kent Rinehart, J.
• Format: Journal Article
• Language: English
• Published: Chichester, UK John Wiley & Sons, Ltd 01-01-2006; Wiley
• Subjects: Aripiprazole; Biological and medical sciences; carbon-14 synthesis; Contrast media. Radiopharmaceuticals; Medical sciences; Pharmacology. Drug treatments; quinolinone; 5-HT2A serotonin receptor; Partial agonist; carbon-14 synthesis; Radiolabelling; Nitrogen heterocycle; Neuroleptic; Psychotropic; Cinnamic acid; Lactam; Carbon Isotopes; Quinoline derivatives; Aminoether; quinolinone; Aripiprazole; D2 Dopamine receptor; 5-HT1A Serotonine receptor; Chlorine Organic compounds; Bicyclic compound; Aromatic compound; Antagonist; Piperazine derivatives; Chemical synthesis; Carbon 14; Quinolone derivatives
• ISSN: 0362-4803; 1099-1344
• DOI: 10.1002/jlcr.1017

Development of Aripiprazole as an oral treatment of schizophrenia required the synthesis of a suitably labeled drug product for use in human metabolism and pharmacokinetic studies. Due to the potential metabolic degradation of the molecule, a multi‐labeled approach utilizing 14C was adopted. The synthesis of [14C]Aripiprazole was accomplished in separate syntheses from 2,3‐dichloro[U‐14C]aniline and [3‐14C]‐cinnamic acid, respectively. Labeled versions were combined on the basis of molar radioactivity giving a final product with a radiochemical purity of 99.9% and a specific activity of 15.5 µCi/mg. Copyright © 2005 John Wiley & Sons, Ltd.